医疗补助中的药剂师提供者地位:州卫生局局长对政策和实践的看法
1Idaho Department of Health and Welfare, Boise, ID.
Journal of the American Pharmacists Association : JAPhA
|September 28, 2025
概括
爱达荷州 爱达荷州 爱达荷州
科学领域:
- 卫生政策 卫生政策
- 药房实践 在药房实践.
- 获得医疗保健 获得医疗保健 获得医疗保健
背景情况:
- 药剂师面临着在医疗补助中获得全方位提供者地位的重大障碍.
- 过时的报销政策和行政障碍限制了药剂师的范围.
- 扩大药剂师的临床权威往往与补偿平价不匹配.
研究的目的:
- 描述爱达荷州将药剂师纳入其医疗补助计划的创新方法.
- 分析爱达荷州实施的"什么,不是谁"退款框架.
- 为其他寻求加强药剂师参与医疗补助计划的州提供政策路线图.
主要方法:
- 实施一个职业中立的报销框架.
- 法律和监管改革以支持药剂师计费.
- 为药剂师优化提供者注册流程.
- 将药剂师补偿率与中级提供商的补偿率调整.
主要成果:
- 爱达荷州的药剂师现在可以注册为染提供者.
- 已启用使用国家提供商标识符的服务的直接计费.
- 爱达荷州的模型促进了可扩展和适应的药剂师整合.
- 该框架支持两党一致通过政策.
结论:
- 爱达荷州的"什么,不是谁"模式成功地将药剂师纳入医疗补助计划.
- 这种方法提高了医疗保健的获取,特别是在农村地区.
- 爱达荷州的模式为其他州提供了可复制的战略.
相关概念视频
Healthcare Agencies II
1.0K
There are various healthcare agencies in the United States—some of which are managed by religious institutions and others by different government branches.
Parish nursing is a growing specialty nursing profession that focuses on holistic healthcare, health promotion, and illness prevention. It blends professional nursing practice with a health ministry, focusing on health and healing within the context of a Christian community. Parish nurses serve as health educators, referral sources,...
Parish nursing is a growing specialty nursing profession that focuses on holistic healthcare, health promotion, and illness prevention. It blends professional nursing practice with a health ministry, focusing on health and healing within the context of a Christian community. Parish nurses serve as health educators, referral sources,...
1.0K
Standards of Care II
1.0K
Nurses bear specific legal responsibilities under several federal statutes, including:
1.0K
Standards of Care I
1.1K
Federal statutes profoundly impact nursing practice, providing critical guidelines to ensure patient care is equitable, accessible, and of the highest quality. The following laws address distinct aspects of healthcare provision and patient rights:
1.1K
Drug Control Governance: Regulatory Bodies and Their Impact
495
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...
495
Dosage Regimens: Partial Pharmacokinetic Parameters
154
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
154
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
151
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
151


